<!doctype html>
<html lang="en">
  <head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <meta name="description" content="Alcoholic Hepatatis Network Observational Study Eligibility and Enrollment">
    <meta name="author" content="AlcHepNet">
	<meta name="og:image" content="./images/Logo_AlcHepNet_2_Crop.jpg">
    <link rel="icon" href="favicon.ico">
    <title>AlcHepNet - Observational Study Eligibility and Enrollment</title>
    <!-- <link href="https://ummscwmuhs.quickbase.com/up/bn79rmeux/g/re/eg/va/bootstrap.min.css" rel="stylesheet"> -->
	<link href="bootstrap.min.css" rel="stylesheet">
    <link href="main.css" rel="stylesheet">
	
  </head>
  <body>

    <header>

      <nav class="navbar navbar-expand-md navbar-light">
        <a class="navbar-brand" href="#"><img style="max-width: 100%" src="AlcHepNet_Website/AlcHepNet_Logos/Logo_AlcHepNet_4_Edit_2.png" class=" " alt="AlcHepNet is a clinical and translational research initiative funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), a division of NIH." /></a>

          <ul class="navbar-nav mr-auto">
            <li class="nav-item">
              <a class="nav-link" href="index.html">Home</a>
            </li>
            <li class="nav-item dropdown active">
				<a class="dropdown-toggle btn" id="clinical-trials" href="#" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">Clinical Trials <span class="sr-only">(current)</span></a>
				<ul class="dropdown-menu" aria-labelledby="clinical-trials">
					<li class="dropdown-submenu">
						<a class="dropdown-item dropdown-toggle" id="obs-trial" href="#">Observational Trial</a>
						<ul class="dropdown-menu" aria-labelledby="obs-trial">
							<li><a class="dropdown-item" href="./eligibility.html">Eligibility</a></li>
							<li><a class="dropdown-item" href="executive-summary.html">Executive Summary</a></li>
						</ul>
					</li>
					<li class="dropdown-divider"></li>
					<li class="dropdown-submenu">
						<a class="dropdown-item dropdown-toggle" id="int-trial" href="#" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">Interventional Trial</a>
						<ul class="dropdown-menu" aria-labelledby="int-trial">
							<li><a class="dropdown-item" href="interventional-eligibility.html">Eligibility</a></li>
							<li><a class="dropdown-item" href="interventional-executive-summary.html">Executive Summary</a></li>
						</ul>
					</li>
					
				</ul>
            </li>
            <li class="nav-item">
              <a class="nav-link" href="publications.html">Publications &amp; Resources</a>
            </li>
			<li class="nav-item">
              <a class="nav-link" href="site-contact.html">Site Contacts</a>
            </li>

          </ul>
          <span class="navbar-text" >
			<small><a class="nav-link" href="https://ummscwmuhs.quickbase.com/db/bkg46867d">Internal</a></small><br>
			<small><a class="nav-link" href="https://arcsapps.umassmed.edu/redcap/redcap_v8.9.2/index.php?pid=4553">UMMS REDCap</a></small><br>
			<small><a class="nav-link" href="https://redcap.uits.iu.edu/">IU REDCap</a></small><br>
			</span>
      </nav>
    </header>

    <main role="main marketing">
      <div class="container">
        <div class="row featurette">
          <div class="col">
            <h1>AlcHepNet Observational Study Eligibility and Enrollment</h1>
          </div>
        </div>
<div class="tr-indent2 lead">
    <table class="tr-layout_table mx-auto">
      <caption>Eligibility information</caption>
      <thead>
      <tr>
        <th id="elgType"></th>
        <th id="elgData"></th>
      </tr>
      </thead>
            <tbody><tr>
        <td headers="elgType" style="text-align:right;white-space:nowrap;">Ages Eligible for Study: &nbsp; </td>
        <td headers="elgData" style="padding-left:1em">21 Years and older &nbsp; (Adult, Older Adult)</td>
      </tr>
                  <tr>
        <td headers="elgType" style="text-align:right;white-space:nowrap;">Sexes Eligible for Study: &nbsp; </td>
        <td headers="elgData" style="padding-left:1em">All</td>
      </tr>
                              <tr>
        <td headers="elgType" style="text-align:right;white-space:nowrap;">Accepts Healthy Volunteers: &nbsp; </td>
        <td headers="elgData" style="padding-left:1em">Yes</td>
      </tr>
                  <tr>
        <td headers="elgType" style="text-align:right;white-space:nowrap;">Sampling Method: &nbsp; </td>
        <td headers="elgData" style="padding-left:1em">Probability Sample</td>
      </tr>
          </tbody></table>

        <div class="ct-header3" style="margin-top:2ex"><h3>Study Population</h3></div>
    <div class="tr-indent2">Any subject with Alcoholic hepatitis, Heavy healthy drinkers, and Healthy controls</div>
    
    <div class="ct-header3" style="margin-top:2ex"><h4>Criteria</h4></div>
    <div class="tr-indent2"><p style="margin-top:1ex; margin-bottom:1ex;"><b>CASES:</b> Heavy drinkers with alcoholic hepatitis</p><p style="margin-top:1ex; margin-bottom:1ex;"> Inclusion criteria</p>
  <ol style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">A clinical diagnosis of alcoholic hepatitis</li>
    <li style="margin-top:0.7ex;">Serum total bilirubin &gt;3 mg/dL</li>
    <li style="margin-top:0.7ex;">Subject or guardian ability to understand and willingness to provide written consent</li>
    <li style="margin-top:0.7ex;">Age greater or equal to 21 years</li>
    <li style="margin-top:0.7ex;">Re-enrolment of an alcoholic hepatitis donor is permissible up to 4 times if the donor presents with a new episode of alcoholic hepatitis 24 weeks or longer after the most recent enrolment in the study</li>
  </ol>
  <p style="margin-top:1ex; margin-bottom:1ex;">Exclusion criteria</p>
  <ol style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">Liver disease significantly caused by hemochromatosis, autoimmune liver disease, Wilson disease, NAFLD, and acute viral hepatitis</li>
    <li style="margin-top:0.7ex;">(NOTE: The presence of chronic hepatitis C, hepatitis B, or HIV is not exclusion to participation.) Pregnant or breast feeding Based on the judgment of the investigator, subject is not capable of understanding or complying with the study requirements.</li>
  </ol>
  <p style="margin-top:0ex; margin-bottom:1ex;"><b>CONTROLS:</b> Heavy drinkers without significant liver disease </p><p>Inclusion criteria</p>
  <ol style="margin-top:0ex; margin-bottom:1ex;">
  <li>History of chronic alcohol consumption sufficient to cause liver damage. Generally, this is considered to be &gt;40 g/day or &gt;280g/week on average for women and &gt;60 g/day or &gt;420 g/week on average for men, for many years (usually decades). Judgement about chronic alcohol consumption will be made by the site investigator. 
</li><li>  Subject or guardian ability to understand and willingness to provide written consent 
</li><li> Age greater or equal to 21 years </li></ol><p>Exclusion criteria</p>
  <ol style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">Past evidence of alcoholic liver disease, defined as a bilirubin &gt; 2.0 mg/dL, an AST &gt; 1.5 ULN, and any hospital admission for liver disease, or the presence of esophageal varices or ascites (at any time in the past).</li>
    <li style="margin-top:0.7ex;">Liver disease significantly caused by hemochromatosis, autoimmune liver disease, Wilson disease, NAFLD, and acute viral hepatitis (NOTE: The presence of chronic hepatitis C, hepatitis B, or HIV is not exclusion to participation.)</li>
    <li style="margin-top:0.7ex;">Alcohol intake at less than 40 g/day or 280g/week on average for women and 60 g/day or 420 g/week on average for men for longer than the past 28 days</li>
    <li style="margin-top:0.7ex;">If liver stiffness has been assessed within the prior 90 days, then stiffness suggesting fibrosis of F1 or greater is excluded. For Fibroscan, this is a fibrosis score &gt;7.0 kPa.</li>
    <li style="margin-top:0.7ex;">Pregnant or breast feeding</li>
    <li style="margin-top:0.7ex;">
      <p style="margin-top:0ex; margin-bottom:1ex;">Any of the following laboratory abnormalities within 90 days prior to signing the consent.</p>
      <ol style="margin-top:1ex; margin-bottom:1ex;">
        <li style="margin-top:0.7ex;">Total bilirubin: &gt;ULN*</li>
        <li style="margin-top:0.7ex;">
          <p style="margin-top:0ex; margin-bottom:1ex;">INR: &gt; 1.4 5</p>
          <p style="margin-top:0ex; margin-bottom:1ex;">*Individuals with a diagnosis of Gilbert's can have total bilirubin up to 3.0 mg/dL and still be eligible for participation.</p>
        </li>
      </ol>
    </li>
  </ol>
  <p style="margin-top:0ex; margin-bottom:1ex;"><h3>Healthy Controls</h3></p>
  <p style="margin-top:0ex; margin-bottom:1ex;">Inclusion criteria</p>
  <ol style="margin-top:0ex; margin-bottom:1ex;">
<li>  AUDIT-C scores of &lt;4 for men and &lt;3 for women (signifying no alcohol misuse) </li>
<li> Abstinent (consumption of less than one standard drink/week) during the 6 months prior to enrolment </li>
<li> Ability to understand and willingness to provide written consent.</li></ol>
<p> Exclusion criteria</p>
  <ol style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">Clinical history or laboratory evidence of liver disease including alcoholic liver disease, NAFLD, hemochromatosis, alcoholic hepatitis, autoimmune liver disease, Wilson disease, hepatitis C, or hepatitis B.</li>
    <li style="margin-top:0.7ex;">Presence of diabetes (requiring treatment with oral agents or insulin).</li>
    <li style="margin-top:0.7ex;">Significant heart disease (prior history of heart disease, other than hypertension)</li>
    <li style="margin-top:0.7ex;">Chronic lung disease (requiring chronic treatment)</li>
    <li style="margin-top:0.7ex;">Immune related conditions (such as Crohn's disease, rheumatoid arthritis, ulcerative colitis, systemic lupus erythematosus, severe psoriasis, etc.)</li>
    <li style="margin-top:0.7ex;">Known infection with HIV</li>
    <li style="margin-top:0.7ex;">Presumed infection, or use of antibiotics or other medications (e.g., corticosteroids) that would affect immune function, within the past 14 days</li>
    <li style="margin-top:0.7ex;">BMI&gt;35</li>
    <li style="margin-top:0.7ex;">Current or known history of cancer (except in situ carcinoma of the cervix or adequately treated basal or squamous cell carcinoma of the skin) within 5 years prior to enrollment</li>
    <li style="margin-top:0.7ex;">Pregnant or breast feeding</li>
    <li style="margin-top:0.7ex;">
      <p style="margin-top:0ex; margin-bottom:1ex;">Any of the following laboratory abnormalities within 90 days prior to signing the consent.</p>
      <ol style="margin-top:1ex; margin-bottom:1ex;">
        <li style="margin-top:0.7ex;">Hemoglobin: &lt;10 g/dL</li>
        <li style="margin-top:0.7ex;">Conjugated bilirubin: &gt; ULN</li>
        <li style="margin-top:0.7ex;">INR: &gt; 1.4</li>
        <li style="margin-top:0.7ex;">AST: &gt;40 IU/mL</li>
        <li style="margin-top:0.7ex;">ALT: &gt;40 IU/mL</li>
      </ol>
    </li>
    <li style="margin-top:0.7ex;">Based on the judgment of the investigator, subject is not capable of complying with the study requirements</li>
  </ol></div>
    
    
        <hr class="featurette-divider">
		
		<div class="row featurette trial-basis" style="display:none">
          <div class="col">
            <h1>AlcHepNet Clinical Trial Eligibility and Enrollment</h1>
          </div>
        </div>
        <div class="row featurette trial-basis" style="display:none">
          <div class="col">
			
Inclusion Criteria
<ol style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;">AH, as defined by the NIAAA pan-consortia for AH:</li>
<ol style="margin-top:1ex; margin-bottom:1ex;" type="a">
<li style="margin-top:0.7ex;">Onset of jaundice (defined as serum total bilirubin >3 mg/dL) within the prior 8 weeks to
screening visit</li>
<li style="margin-top:0.7ex;">Regular consumption of alcohol with an intake of > 40 gm daily or >280gm weekly
on average for women and > 60 gm daily or >420gm weekly on average for men
for 6 months or more, with less than 8 weeks of abstinence before onset of jaundice</li>
<li style="margin-top:0.7ex;">AST > 50 IU/l</li>
<li style="margin-top:0.7ex;">AST:ALT > 1.5 and both values < 400 IU/l</li>
<li style="margin-top:0.7ex;">and/or histological evidence of AH*</li>
<p>* In patients with possible AH or AH with confounding factors such as possible ischemic
hepatitis, possible DILI, uncertain history of alcohol use (e.g., patient denies excessive alcohol
use), and atypical/abnormal laboratory tests (e.g., AST < 50 IU/mL or > 400 IU/mL,
AST/ALT ratio < 1.5), antinuclear antibody > 1:160 or SMA > 1:80, a liver biopsy will be
performed to confirm AH and exclude competing etiologies</p>
</ol>
<li style="margin-top:0.7ex;">MELD 20-35 on day of randomization.
</li>
</ol>
Exclusion Criteria
<ol style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;">MELD SCORE <20 or > 35</li>
<li style="margin-top:0.7ex;">Active sepsis (positive blood or ascitic cultures) with Systemic Inflammatory Response
Syndrome (SIRS) or hemodynamic compromise requiring intravenous pressors to
maintain tissue perfusion</li>
<li style="margin-top:0.7ex;">Pneumonia as evidenced by radiological exam</li>
<li style="margin-top:0.7ex;">Multi-organ failure</li>
<li style="margin-top:0.7ex;">Renal failure defined by GFR <50 mL/min.</li>
<li style="margin-top:0.7ex;">Clinically active C. diff infection</li>
<li style="margin-top:0.7ex;">History of imaging of the liver (ultrasound, computerized tomography or magnetic
resonance) showing other causes of jaundice</li>
<li style="margin-top:0.7ex;">History of other liver diseases including hepatitis B (positive HBsAg or HBV DNA),
hepatitis C (positive HCV RNA), autoimmune hepatitis, Wilson disease, genetic
\hemochromatosis, alpha1-antitrypsin deficiency or strong suspicion of Drug Induced
Liver Injury (DILI)</li>
<li style="margin-top:0.7ex;">History of HIV infection (positive HIV RNA or on treatment for HIV infection)</li>
<li style="margin-top:0.7ex;">History or presence of cancer (including hepatocellular carcinoma) other than nonmelanoma
skin cancer</li>
<li style="margin-top:0.7ex;">History of other significant medical problems such as autoimmune diseases, severe
asthma, psoriasis, Inflammatory Bowel Disease (IBD), etc. that might require
immunosuppressive treatments</li>
<li style="margin-top:0.7ex;">Pregnancy or breastfeeding</li>
<li style="margin-top:0.7ex;">Prior exposure to experimental therapies in last 3 months</li>
<li style="margin-top:0.7ex;">Prior exposure to systemic corticosteroid (glucocorticoid) or immunosuppressive therapy
for more than 4 days within previous 30 days</li>
<li style="margin-top:0.7ex;">Need for inotropic pressor support to maintain perfusion to critical organs within prior
48 hours before randomization and initiation of experimental treatment</li>
<li style="margin-top:0.7ex;">Clinically significant pancreatitis- abdominal pain, elevated lipase (> 3 X ULN) and at least
edema of pancreas with fat-stranding on CT scan</li>
<li style="margin-top:0.7ex;">Total WBC count > 30000/mm3</li>
<li style="margin-top:0.7ex;">Known allergy or intolerance to therapeutic agents to be tested</li>
<li style="margin-top:0.7ex;">Inability to voluntarily obtain informed consent from participant or guardian</li>
<li style="margin-top:0.7ex;">Perceived inability to follow study procedures and comply with protocol</li>
<li style="margin-top:0.7ex;">Platelet count < 50,000.</li>
</ol>
The participants for this study will be recruited from a hospitalized population of participants
meeting the eligibility criteria outlined above who live within one day travel from one of the
participating clinical centers and who have provided informed consent to participate in this
clinical trial and who are willing to continue their participation for the anticipated follow-up
period of the trial. Although the primary endpoint is survival at 90 days, follow-up visits will be
continued up to 6 months.
           
        </div> </div>
        <hr class="featurette-divider">
        <div class="row featurette">
          <div class="col">
          <h2 class="featurette-heading">AlcHepNet Organizations</h2>
            <img class="org-logo img-fluid mx-auto" src="new-site-logos.png" alt="Participating organization logos"/>
          </div>
        </div>

        <hr class="featurette-divider">

        <div class="row featurette">
        <div class="col text-center">
			<p class="lead">AlcHepNet is a clinical and translational research initiative funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), a division of NIH.</p>
         </div>
        </div>
        <!-- /END THE FEATURETTES -->
<hr class="featurette-divider">
      </div><!-- /.container -->


      <!-- FOOTER -->
      <footer class="container">
      <div class="row">
        <div class="col text-left">
        <p>&copy; 2017-2018 Alcoholic Hepatitis Network <!-- &middot; <a href="#">Privacy</a> &middot; <a href="#">Terms</a> --></p>
        </div>
         <div class="col text-right">
        <p class="float-right"><a href="#">Back to top</a></p>
        </div>
        </div>
      </footer>
      </div>
    </main>

    <!-- Bootstrap core JavaScript
    ================================================== -->
    <script src="jquery-3.3.1.slim.min.js"></script>
    <script src="popper.min.js"></script>
    <script src="bootstrap.min.js"></script>
	<script src="main.js"></script>
  </body>
</html>
